Market research
MORF Morphic Holding Inc
Current ticker: MORF
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 56.13
- Dividend yield
- Not available
- Beta
- 1.49
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 56.13
- Dividend yield
- Not available
- Beta
- 1.49
About
About Morphic Holding Inc
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Research context
Morphic Holding Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MORF discussion.
5 years, 7 months ago
Morphic Holding, Inc is currently in a long term uptrend where the price is trading 32.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 44.2.
Morphic Holding, Inc's total revenue rose by 1866.8% to $6M since the same quarter in the previous year.
Its net income has increased by 10.5% to $-18M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.0% to $-14M since the same quarter in the previous year.
Based on the above factors, Morphic Holding, Inc gets an overall score of 5/5.